U.S. Hemophilia Treatment Market is driven by recombinant therapies

ein Foto hinzugefügt Andere

2025-06-16 07:26:09 -

The U.S. hemophilia treatment market encompasses a diverse portfolio of therapeutic options, including factor VIII and IX replacement products, bypassing agents, and emerging gene therapies designed to prevent and manage bleeding episodes in patients with hemophilia A and B. Recombinant factor concentrates provide consistent purity levels and eliminate the risk of blood‐borne pathogen...

0 Kommentare 0 Geteilt 6 Ansichten 0 Bewertungen